STOCK TITAN
  1. Home
  2. News
  3. TXG

10x Genomics Inc - TXG STOCK NEWS

Welcome to our dedicated news page for 10x Genomics (Ticker: TXG), a resource for investors and traders seeking the latest updates and insights on 10x Genomics.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect 10x Genomics's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of 10x Genomics's position in the market.

News
10x Genomics to Report First Quarter 2024 Financial Results on April 30, 2024
Rhea-AI Summary
10x Genomics, Inc. (TXG) will release its financial results for Q1 2024 on April 30, 2024. A conference call and webcast will follow to discuss results, business updates, and future prospects.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.95%
Tags
conferences earnings
-
News
10x Genomics Commercially Launches Visium HD Spatial Gene Expression Assay
Rhea-AI Summary
10x Genomics, Inc. (TXG) launches Visium HD Spatial Gene Expression product, enabling whole transcriptome spatial discovery at single cell–scale resolution. The product offers comprehensive characterization of FFPE tissue samples, combining transcriptome spatial discovery with histological insights. Visium HD provides best-in-class sequencing-based spatial transcriptomics data, FFPE compatibility, enhanced histology, and easy-to-use analysis and visualization tools.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.17%
Tags
none
-
News
10x Genomics Expands Xenium Menu with Multi-Modal Cell Segmentation Kit and Immuno-Oncology Gene Panel
Rhea-AI Summary
10x Genomics, Inc. announces the commercial availability of the Xenium Cell Segmentation Kit and the launch of the Xenium Immuno-Oncology Panel. The company aims to enhance single cell spatial analysis with advanced AI algorithms and diverse stains, catering to researchers' needs for accurate cell segmentation and in-depth tumor microenvironment analysis.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.5%
Tags
none
News
10x Genomics Begins Commercial Shipments of Chromium GEM-X Products
Rhea-AI Summary
10x Genomics, Inc. introduces GEM-X technology architecture, enhancing single cell analysis with improved sensitivity, scalability, cost-efficiency, and data quality. The new products, Chromium Single Cell Gene Expression 3' v4 and Chromium Single Cell Immune Profiling 5' v3, offer superior performance and workflow advantages.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.37%
Tags
none
-
News
10x Genomics to Present at the 44th Annual TD Cowen Health Care Conference
Rhea-AI Summary
10x Genomics, Inc. (TXG) will participate in a fireside chat at the 44th Annual TD Cowen Health Care Conference. The event will be live-streamed on their website, with a replay option available for 45 days.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.79%
Tags
conferences
-
News
10x Genomics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Outlook for 2024
Rhea-AI Summary
10x Genomics (TXG) reports Q4 2023 revenue growth of 18% and FY 2023 revenue growth of 20% over 2022. The company launched new products, increased instruments sold, and provided a positive outlook for 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.79%
Tags
earnings
News
10x Genomics Expands Leadership in Single Cell Analysis with Launch of GEM-X Technology
Rhea-AI Summary
10x Genomics, Inc. (Nasdaq: TXG) has announced the launch of GEM-X, the next generation of the company's leading single cell technology, offering higher performance at larger scale and lower cost. The company is now accepting preorders for the first two product launches powered by the GEM-X technology architecture, Chromium Single Cell Gene Expression 3'v4 and Chromium Single Cell Immune Profiling 5'v3, with expected shipping in Q1. GEM-X offers substantial performance advantages, including increased sensitivity, scalability, cost-effectiveness, enhanced data quality, maximum sample recovery, and improved assay robustness, setting a new standard for single cell analysis.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.26%
Tags
none
-
News
10x Genomics to Showcase New Cutting-Edge Technologies and Highlight Innovation Roadmap at 2024 AGBT General Meeting
Rhea-AI Summary
10x Genomics, Inc. (Nasdaq: TXG) has announced a series of new products and technology demonstrations that will be presented at the 2024 Advances in Genome Biology and Technology (AGBT) General Meeting. The new products aim to deliver higher performance, improve ease of use, and enable researchers to measure more biology. These include Visium HD for spatial discovery, Xenium In Situ platform for in situ analysis, and new capabilities for its Chromium Flex assay for single cell workflows. The company will also share new data and development directions across its three platforms at a workshop during the event.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.41%
Tags
none
-
News
10x Genomics to Report Fourth Quarter and Full Year 2023 Financial Results on February 15, 2024
Rhea-AI Summary
10x Genomics, Inc. (TXG) will release its financial results for Q4 and full year 2023 on February 15, 2024. The company will host a conference call and live webcast to discuss the results, business developments, and outlook. The webcast will be accessible on the company's website and archived for replay.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.02%
Tags
conferences earnings
News
10x Genomics Announces Preliminary Fourth Quarter and Full Year 2023 Results
Rhea-AI Summary
10x Genomics, a leader in single cell and spatial biology, announced preliminary, unaudited select results for the fourth quarter and full year ended December 31, 2023. Revenue for the fourth quarter was approximately $184.0 million, with 18% growth over the corresponding prior year period. Full year revenue was approximately $618.7 million, representing 20% growth over the prior year. Instruments revenue saw significant growth, with approximately $123.5 million for the full year. The company also increased cumulative instruments sold to more than 5,900 as of the end of 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.43%
Tags
earnings
Stock TXG logo
10x Genomics Inc

Nasdaq:TXG

TXG Rankings

#1445 Ranked by Market Cap
#596 Ranked by Stock Gains
N/A Ranked by Dividends

TXG Stock Data

4.12B
102.65M
2.38%
92.4%
7.15%
Testing Laboratories
Professional, Scientific, and Technical Services
Link
US
Pleasanton

About TXG

advancing human health requires a greater understanding of biology, and that understanding starts with the cell. we enable researchers to drive exponential progress in oncology, immunology, neuroscience, and more with novel single cell, spatial, and in situ tools that have been cited in over 3,000 publications and continually improved by our dedicated scientific team. our aim: to develop innovative instruments, reagents, and software that allow you to see your biological system at a resolution that matches its complexity.